Biosimilars—here to stay (Updated July 2021)

Up until now, most biosimilars have been in the domain of public and private hospitals, however the release shortly of biosimilar adalimumab, which is currently a self-administered subcutaneous injection, means biosimilars will come into the domain of primary care and community pharmacists. It has never been more important for community pharmacists to educate themselves about

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?